Alliqua Biomedical (ALQA) Earns Daily News Sentiment Score of 0.21

News articles about Alliqua Biomedical (NASDAQ:ALQA) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alliqua Biomedical earned a news impact score of 0.21 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.4385982076181 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several research firms recently commented on ALQA. HC Wainwright set a $5.00 price objective on shares of Alliqua Biomedical and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. ValuEngine upgraded shares of Alliqua Biomedical from a “sell” rating to a “hold” rating in a research note on Friday, October 6th. Finally, Zacks Investment Research lowered shares of Alliqua Biomedical from a “buy” rating to a “hold” rating in a research note on Wednesday, September 20th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Alliqua Biomedical currently has an average rating of “Hold” and a consensus target price of $8.20.

Alliqua Biomedical (ALQA) traded up $0.03 during midday trading on Monday, hitting $2.03. 48,100 shares of the company traded hands, compared to its average volume of 245,756. Alliqua Biomedical has a 1 year low of $1.73 and a 1 year high of $8.50. The company has a market cap of $10.13, a price-to-earnings ratio of -0.21 and a beta of 0.84.

Alliqua Biomedical (NASDAQ:ALQA) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.76). Alliqua Biomedical had a negative net margin of 155.55% and a negative return on equity of 110.42%. analysts expect that Alliqua Biomedical will post -3.85 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Alliqua Biomedical (ALQA) Earns Daily News Sentiment Score of 0.21” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2018/01/15/alliqua-biomedical-alqa-earns-daily-news-sentiment-score-of-0-21.html.

About Alliqua Biomedical

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Insider Buying and Selling by Quarter for Alliqua Biomedical (NASDAQ:ALQA)

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply